SPORE Leukemia Tissue Bank

SPORE白血病组织库

基本信息

  • 批准号:
    7715181
  • 负责人:
  • 金额:
    $ 11.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-01 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

On order to successfully translate basic research in leukemia to the clinical setting, as well as to better understand the relevance of observed clinical or population-based phenomena through laboratory-based research, an extensive repository of tissue samples, with accompanying pathologic and clinical data, procured from leukemia patients is necessary. To fulfill this role. Core A will provide researchers in the Leukemia SPORE access to a relatively unprecedented repository of uniformly prepared and fully characterized leukemia patient samples. The already well-established Ohio State University and CALGB Leukemia Tissue Banks (referred to as SPORE LTBs) constitute the backbone of Core A, and contribute crucial experience and infrastructure to this effort. The SPORE LTBs serves as centralized tissue banks of blood and bone marrow specimens, as well as non-leukemic material, procured from leukemia patients enrolled on CALGB or OSU treatment protocols, and provide these to investigators within and outside of OSU. This work will integrate with Cores B (biostatistics) and C (Biomedical informatics) to maintain a detailed, current database of samples and accompanying clinical information available. Beyond simply serving as a cell repository. Core A will perform regular validation of sample quality, conduct molecular characterizations, and prepare derivatives (protein, DNA, RNA). The availability of this infrastructure for procuring samples, and the large number of samples already in our possession, will greatly facilitate the conduct of the research projects of this SPORE proposal as well as provide an important and widely available resource for extended studies by investigators within this or outside the OSU Leukemia SPORE. The specific aims of Core A are: (1) To provide central collection, processing and a state-of- the-art repository for samples collected from leukemia patients treated on clinical protocols that are relevant to the OSU Leukemia SPORE; (2) To provide materials from processed clinical samples to interested investigators, within and outside of the OSU Leukemia SPORE, who examine relevant cellular and molecular properties of leukemia and correlate these properties with clinical or population-based outcomes and who commit to sharing the data derived from their research efforts. The effective collection and characterization of leukemia samples by Core A and their provision to SPORE investigators is critical to the success of the research proposed. The infrastructure of this Core A is therefore already in place, and partially supported through NCI funding through both the CALGB and OSUCCC, In this Core proposal, we seek supplemental and not overlapping funding for support ofthe SPORE projects RELEVANCE (See instructions): Biological mechanistic investigations rely on cell lines or animal models. While these are powerful research tools, validating laboratory findings in human tissue is crucial to understand their relevance to human disease. This Core will provide SPORE researchers with simplified access to a large repository of leukemia patient samples and accompanying clinical information. This multi-tiered effort is essential to the overall goal of this SPORE group to bring their findings to the practical benefit of patients with leukemia.
为了成功地将白血病的基础研究转化为临床环境, 通过基于实验室的研究,了解观察到的临床或基于人群的现象的相关性, 研究,一个广泛的组织样本库,伴随病理和临床数据,采购 白血病患者是必要的。去完成这个角色。核心A将为白血病孢子研究人员提供 获得了相对前所未有的统一准备和充分表征的白血病患者库, 样品已经建立完善的俄亥俄州州立大学和CALGB白血病组织库(简称: 作为SPORE LTB)构成了核心A的骨干,并为此贡献了关键的经验和基础设施 努力SPORE LTB用作血液和骨髓标本的集中组织库,以及 从CALGB或OSU治疗方案中招募的白血病患者中获得的非白血病材料,以及 向OSU内外的调查人员提供这些信息。这项工作将与核心B(生物统计学)和 C(生物医学信息学)维护详细的当前样本数据库和随附的临床数据库 information available.不仅仅是作为一个细胞库。核心A将定期验证 样品质量、进行分子表征和制备衍生物(蛋白质、DNA、RNA)。的 这一采购样品的基础设施的可用性,以及我们已经在 拥有,将极大地促进本SPORE建议的研究项目的进行,并提供 这是一个重要的和广泛可用的资源,供俄勒冈州立大学内外的研究人员进行扩展研究 白血病孢子。核心A的具体目标是:(1)提供中央收集、处理和国家信息系统, 从按照临床方案治疗的白血病患者收集的样本的最先进的储存库, OSU白血病孢子;(2)为感兴趣的人提供来自处理过的临床样本的材料 研究人员,内外的OSU白血病孢子,谁检查相关的细胞和分子 白血病的性质,并将这些性质与临床或基于人群的结果相关联, 承诺分享从他们的研究工作中获得的数据。有效收集和定性 核心A的白血病样本及其提供给SPORE研究人员对研究的成功至关重要 提出了因此,核心A的基础设施已经到位,并通过NCI提供部分支持 通过CALGB和OSUCCC提供资金,在此核心提案中,我们寻求补充,而不是 为支持SPORE项目提供重叠资金 相关性(参见说明): 生物学机制研究依赖于细胞系或动物模型。虽然这些都是强有力的研究 工具,验证人体组织中的实验室发现对于了解它们与人类的相关性至关重要 疾病该核心将为SPORE研究人员提供简化的访问大型白血病库的权限 患者样本和随附的临床信息。这种多层次的努力对实现总体目标至关重要 这个孢子小组的成员,把他们的发现带给白血病患者的实际利益。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GUIDO MARCUCCI其他文献

GUIDO MARCUCCI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GUIDO MARCUCCI', 18)}}的其他基金

The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML
miR-142 在克隆性造血障碍转化为 AML 中的作用
  • 批准号:
    10367856
  • 财政年份:
    2022
  • 资助金额:
    $ 11.47万
  • 项目类别:
The Role of miR-142 in the Transformation of Clonal Hematopoietic Disorders into AML
miR-142 在克隆性造血障碍转化为 AML 中的作用
  • 批准号:
    10544734
  • 财政年份:
    2022
  • 资助金额:
    $ 11.47万
  • 项目类别:
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
骨髓白血病微环境中的血管重塑:治疗目标?
  • 批准号:
    10371023
  • 财政年份:
    2020
  • 资助金额:
    $ 11.47万
  • 项目类别:
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
骨髓白血病微环境中的血管重塑:治疗目标?
  • 批准号:
    10094210
  • 财政年份:
    2020
  • 资助金额:
    $ 11.47万
  • 项目类别:
Vascular Remodeling in the Bone Marrow Leukemic Niche: A Therapeutic Target?
骨髓白血病微环境中的血管重塑:治疗目标?
  • 批准号:
    10600088
  • 财政年份:
    2020
  • 资助金额:
    $ 11.47万
  • 项目类别:
Validation of microRNAs as therapeutic targets in hematological malignancies
验证 microRNA 作为血液恶性肿瘤治疗靶点
  • 批准号:
    8815267
  • 财政年份:
    2011
  • 资助金额:
    $ 11.47万
  • 项目类别:
Validation of microRNAs as therapeutic targets in hematological malignancies
验证 microRNA 作为血液恶性肿瘤治疗靶点
  • 批准号:
    8627134
  • 财政年份:
    2011
  • 资助金额:
    $ 11.47万
  • 项目类别:
Molecular characterization of normal cytogenetics AML in older patients
老年患者正常细胞遗传学 AML 的分子特征
  • 批准号:
    7471096
  • 财政年份:
    2008
  • 资助金额:
    $ 11.47万
  • 项目类别:
Molecular characterization of normal cytogenetics AML in older patients
老年患者正常细胞遗传学 AML 的分子特征
  • 批准号:
    7614313
  • 财政年份:
    2008
  • 资助金额:
    $ 11.47万
  • 项目类别:
Pharmacologic modulation of chromatin remodeling in leu*
leu* 染色质重塑的药理学调节
  • 批准号:
    7096021
  • 财政年份:
    2005
  • 资助金额:
    $ 11.47万
  • 项目类别:

相似海外基金

Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
  • 批准号:
    19K08356
  • 财政年份:
    2019
  • 资助金额:
    $ 11.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
  • 批准号:
    23501309
  • 财政年份:
    2011
  • 资助金额:
    $ 11.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
  • 批准号:
    3556971
  • 财政年份:
    1980
  • 资助金额:
    $ 11.47万
  • 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
  • 批准号:
    3556968
  • 财政年份:
    1980
  • 资助金额:
    $ 11.47万
  • 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
  • 批准号:
    3889304
  • 财政年份:
  • 资助金额:
    $ 11.47万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了